Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Cancer Institute (NCI)
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCI-2013-02097 | P1 |
Completed |
Melanoma |
2013-09-01 |
|
NCI-2013-02096 | P2 |
Completed |
Melanoma |
2013-09-01 |
|
MCC-15280 | P1 |
Completed |
Melanoma |
2012-04-01 |
|
99-C-0158 | P2 |
Completed |
Melanoma |
2010-05-01 |